Prothionamide
Showing 1 - 16 of 16
MDR-TB Trial in Worldwide (Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline), Moxifloxacin, Clofazimine)
Active, not recruiting
- MDR-TB
- Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
- +9 more
-
Addis Ababa, Ethiopia
- +12 more
Oct 12, 2022
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis Trial in China (Bedaquiline, Delamanid, Contezolid)
Not yet recruiting
- Pulmonary Tuberculosis
- Rifampicin-resistant Tuberculosis
- Bedaquiline
- +11 more
-
Beijing, Beijing, China
- +37 more
Oct 11, 2023
Antiretroviral Drugs and Related Drugs During and After
Multi-drug Resistant Tuberculosis Trial in Lambarene (Km+ Mfx+ Pto + H + Cfz +E+Z)
Recruiting
- Multi-drug Resistant Tuberculosis
- Km+ Mfx+ Pto + H + Cfz +E+Z
-
Lambarene, Please Select, GabonCentre de Recherches Médicales de Lambaréné
Jul 26, 2021
Tuberculosis Trial in Beijing (Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.)
Unknown status
- Tuberculosis
- Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
-
Beijing, Beijing, ChinaBeijing Chest Hospital affiliated to Capital Medical University
Sep 11, 2020
Multidrug Resistant Tuberculosis Trial in China (PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter
Recruiting
- Multidrug Resistant Tuberculosis
- PZA sensitivity guided ultra-short all Oral Regimen
- Standardized Shorter Regimen
-
Shenzhen, Guangzhou, China
- +13 more
Jul 22, 2020
Tuberculosis, Multidrug-Resistant Trial in Cape Town (Targeted sequencing using the GenoScreen Deeplex assay)
Not yet recruiting
- Tuberculosis, Multidrug-Resistant
- Targeted sequencing using the GenoScreen Deeplex assay
-
Cape Town, Western Cape, South AfricaUniversity of Cape Town
Sep 28, 2021
Pulmonary Tuberculosis TB in Sputum: (+) Microscopy Trial in Shanghai (Group A (the standard 2HRZE/4HR regimen), Group B (New
Completed
- Pulmonary Tuberculosis TB in Sputum: (+) Microscopy
- Group A (the standard 2HRZE/4HR regimen)
- Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
-
Shanghai, China
- +3 more
Nov 5, 2020
Multidrug Resistant Tuberculosis Trial in China (WHO-approved MDR-TB regimen, NGS-guided regimen: Regimen A, NGS-guided regimen:
Not yet recruiting
- Multidrug Resistant Tuberculosis
- WHO-approved MDR-TB regimen
- +3 more
-
Shenzhen, Guangzhou, China
- +11 more
Jul 19, 2018
Salivary Therapeutic Drug Monitoring of Anti-Tuberculosis Drugs
Completed
- Tuberculosis
- Saliva sampling
- Plasma/serum sampling
-
Haren, Groningen, NetherlandsUniversity Medical Center Groningen (UMCG) Beatrixoord
Nov 20, 2018
Tuberculosis Multi Drug Resistant Active Trial (Delamanid, Linezolid, Levofloxacin)
Withdrawn
- Tuberculosis Multi Drug Resistant Active
- Delamanid
- +4 more
- (no location specified)
Sep 7, 2017
MDR TB Trial in Nanjing (RhIL-2)
Unknown status
- MDR TB
-
Nanjing, Jiangsu, Chinathe First Affiliated Hospital of Nanjing Medical University
Feb 27, 2017
Simplified Short Regimen for Multidrug Resistant Tuberculosis in
Unknown status
- Multidrug Resistant Tuberculosis
- Short course MDR-TB treatment regimen
-
Nukus, Karakalpakstan, UzbekistanOutpatient clinics in three districts
Jul 9, 2015
Healthy Trial in Seoul (Levofloxacin and Streptomycin added, Moxifloxacin and Kanamycin added)
Completed
- Healthy
- Levofloxacin and Streptomycin added
- Moxifloxacin and Kanamycin added
-
Seoul, Korea, Republic ofSeoul National University Bundang Hospital
Apr 29, 2014
Multidrug Resistant Tuberculosis Trial in China (Pyrazinamide containing regimen, Regimen without Pyrazinamide)
Unknown status
- Multidrug Resistant Tuberculosis
- Pyrazinamide containing regimen
- Regimen without Pyrazinamide
-
Chongqing, Chongqing, China
- +10 more
Apr 21, 2014